Vaxcyte, Inc. (PCVX) — 10-Q Filings
All 10-Q filings from Vaxcyte, Inc.. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 6, 2026
-
Vaxcyte's R&D Soars, Net Loss Widens to $520M Amid Vaccine Push
— Nov 4, 2025 Risk: high
Vaxcyte, Inc. (PCVX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $520.1 million, a substantial rise from -
Vaxcyte's Q2 Losses Widen Amid Accelerated R&D for Key Vaccines
— Aug 6, 2025 Risk: high
Vaxcyte, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for the thr -
Vaxcyte, Inc. Files Q1 2025 10-Q Report
— May 7, 2025 Risk: medium
Vaxcyte, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. K -
Vaxcyte, Inc. Files Q3 2024 10-Q Report
— Nov 5, 2024 Risk: medium
Vaxcyte, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business operation -
Vaxcyte, Inc. Files Q2 2024 10-Q Report
— Aug 6, 2024 Risk: medium
Vaxcyte, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations. Key fi -
Vaxcyte, Inc. Files 10-Q for Q1 2024
— May 8, 2024 Risk: low
Vaxcyte, Inc. (PCVX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Vaxcyte, Inc. filed a 10-Q report for the period ending March 31, 2024. The co
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX